Tencent: Investment Portfolio & Startup News
Tencent
To add a bio or update investment portfolio click update information.
Investment Portfolio


T-Therapeutics closes a £100m Series B led by Advent Life Sciences and British Business Bank to take its cancer and autoimmune treatments into clinical trials
T-Therapeutics is a biotechnology company developing T cell engager treatments based on human T cell receptors. Its drug programmes target cancer and autoimmune diseases.


Primer announces £75m Series C led by Sofina for unified payments and finance infrastructure
Primer is a payments infrastructure platform that gives merchants a unified layer across the payments lifecycle, from checkout to payout. The platform helps payments, finance and treasury teams manage transaction data, payment providers and reconciliation from a single system.


T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
- 2(12 months)
- tencent.com/en-us
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech